Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer

Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer

Background Triple-negative breast cancer (TNBC) corresponds to approximately 20% of all breast tumors, with a high propensity for metastasis and a poor prognosis. Because TNBC displays a high mutational load compared with other breast cancer types, a neoantigen-based immunotherapy strategy could be...

Full description

Bibliographic Details
Main Authors: Jun Wang, Peng Liu, Nicholas Lemoine, Yaohe Wang, Louisa S Chard Dunmall, Carmela Di Gioia, Claude Chelala, Renato Brito Baleeiro, Ai Nagano, Lauren Cutmore, Lydon Wainaina Nyambura, Peter Walden
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/8/e007336.full

Internet

https://jitc.bmj.com/content/11/8/e007336.full

Similar Items